Compile Data Set for Download or QSAR
maximum 50k data
Found 8 Enz. Inhib. hit(s) with Target = 'Complement factor B' and Ligand = 'BDBM160475'
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160475(US10093663, Example 26b | US9682968, Example-26a)
Affinity DataIC50:  0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160475(US10093663, Example 26b | US9682968, Example-26a)
Affinity DataIC50:  10nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160475(US10093663, Example 26b | US9682968, Example-26a)
Affinity DataIC50:  12nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor B(Mus musculus)
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM160475(US10093663, Example 26b | US9682968, Example-26a)
Affinity DataIC50:  110nMAssay Description:Inhibition of serine protease factor B in 50% mouse serum assessed as reduction in C3b deposition pre-incubated for 15 mins before activated zymosan ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160475(US10093663, Example 26b | US9682968, Example-26a)
Affinity DataIC50:  130nMAssay Description:Inhibition of serine protease factor B in 50% human whole blood assessed as reduction in alternative pathway-mediated membrane attack complex formati...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160475(US10093663, Example 26b | US9682968, Example-26a)
Affinity DataIC50:  400nMAssay Description:Inhibition of human serine protease factor B in human PNH patient derived sample assessed as prevention of erythrocyte lysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160475(US10093663, Example 26b | US9682968, Example-26a)
Affinity DataIC50:  1.10E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement factor B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM160475(US10093663, Example 26b | US9682968, Example-26a)
Affinity DataKd:  7.90nMAssay Description:Binding affinity to human serine protease factor B by SPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed